Results 41 to 50 of about 206,755 (278)

Evaluation and management of platelet transfusion refractoriness

Blood Research, 2022
Platelet transfusion refractoriness (PTR), in which platelet counts do not increase after transfusion, occurs in many patients receiving platelet transfusions. PTR is a clinical condition that can harm patients. The causes of PTR can be divided into two types: immune and non-immune. Most cases of PTR are non-immune. Among immune causes, the most common
Youk, Hee-Jeong, Hwang, Sang-Hyun, Oh, Heung-Bum, Ko, Dae-Hyun   +3 more
openaire   +2 more sources

Platelet compatibility and platelet antibodies detection: A step towards resolving dilemma in management of platelet refractoriness in oncology patients

Global Journal of Transfusion Medicine, 2019
Background: Platelet refractoriness complicates the provision of platelet transfusions- a critical and essential part in management of thrombocytopenia in Oncology patients. Platelet refractoriness poses challenge due to alloimmunization to HLA (Class I)
Sadhana Mangwana, Atin Kacker, Nikhil Simon   +2 more
doaj   +1 more source

Establishment and evaluation of predictive models of platelet transfusion effect in multi-center tumor patients

Zhongguo shuxue zazhi, 2023
Objective To study the platelet transfusion predictive models in tumor patients and evaluate its application effect. Methods A retrospective study was conducted on 944 tumor patients, including 533 males and 411 females who received platelet transfusion ...
Gang ZHAO, Fan GUO, Qing LI, Yihua XIE, Jun LI   +4 more
doaj   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon, Roseline d’Oiron, Rainer B. Zotz, Niels Bindslev, Matteo Nicola Dario Di Minno, Giovanni Di Minno   +5 more
doaj   +1 more source

Efficacy of apheresis and concentrated platelets under different transfusion strategies

Zhongguo shuxue zazhi, 2022
Objective To retrospectively analyze the clinical effects of apheresis and concentrated platelets under different transfusion strategies, so as to explore more scientific transfusion strategies.
Meihong CHEN, Jiafu HUANG
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Contemporary management of pain in cirrhosis: Toward precision therapy for pain

Hepatology, EarlyView., 2022
Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman, Neehar Parikh, Dan J. Clauw, David A. Williams, Elliot B. Tapper   +4 more
wiley   +1 more source

iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity

Stem Cell Reports, 2020
Summary: The ex vivo production of platelets depleted of human leukocyte antigen class I (HLA-I) could serve as a universal measure to overcome platelet transfusion refractoriness caused by HLA-I incompatibility.
Daisuke Suzuki, Charlotte Flahou, Norihide Yoshikawa, Ieva Stirblyte, Yoshikazu Hayashi, Akira Sawaguchi, Marina Akasaka, Sou Nakamura, Natsumi Higashi, Huaigeng Xu, Takuya Matsumoto, Kosuke Fujio, Markus G. Manz, Akitsu Hotta, Hitoshi Takizawa, Koji Eto, Naoshi Sugimoto   +16 more
doaj   +1 more source

Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim

, 2022
Immune-mediated platelet transfusion refractoriness due to anti-human leukocyte antigen (HLA) antibodies can occur in approximately 9% of patients with myelodysplastic syndromes (MDS) and can lead to an increased risk of clinically relevant bleeds ...
Čengić, Marina, Skorić, Ivana, Ivana Skorić, Ivan Krečak, Marina Čengić, Filip Krečak, Skelin, Marko, Marko Skelin, Krečak, Ivan, Krečak, Filip   +9 more
core   +1 more source

Factors affecting the efficacy of platelet transfusion and specificity of HLA-Ⅰ antibodies in tumor patients

Zhongguo shuxue zazhi, 2023
Objective To analyze the factors affecting the efficacy of platelet transfusion and the specificity of HLA-Ⅰ antibodies in tumor patients. Methods Tumer patients applied for platelet transfusion from November 2019 to July 2021 in Sichuan Cancer Hospital ...
Juan SAI, Shanshan WAN, Li TIAN
doaj   +1 more source